We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Medipan to Distribute Pronostics' Autoimmune Diagnostics in Germany and Austria

By HospiMedica staff writers
Posted on 17 Mar 2008
Pronostics Ltd. (Cambridge, UK), a developer and manufacturer of next-generation multiplexed diagnostics, has signed a distribution agreement with Medipan GmbH (Berlin, Germany) for its autoimmune disease biomarker assays. Medipan, which distributes in vitro diagnostic tests in the field of autoimmunity, will have an exclusive license to sell Pronostics' UltraPlex ANA, coeliac, and thyroid assays in Germany and Austria.

Germany is Europe's largest market for diagnostic products. As part of the agreement, Medipan will market the assays to hospitals and large private laboratories. The deal could initially generate up to US$3.1 million (€2 million) in revenues.

UltraPlex assays provide a powerful tool for rapid, accurate, and inexpensive diagnosis of autoimmune diseases. UltraPlex is a highly accurate, digital multiplexing solution that enables tens to hundreds of tests to be performed simultaneously in a single assay using a microscopic bar-coding system. Pronostics lead product, the UltraPlex ANA assay, which consists of 11 tests in one, provides valuable time and cost savings compared to existing serial testing approaches using panels of human epithelial type 2 cell (Hep-2) screens and enzyme-linked immunosorbant assays (ELISAs). It allows hospitals and laboratories to perform fully automated profiles of patient samples and gives both quantitative and qualitative results for antibodies to autoimmune diseases.

Dr Dirk Roggenbuck, CEO of Medipan, said: "We are very pleased to have been chosen as the distributor for the UltraPlex range of autoimmune assays. The UltraPlex platform is more efficient and economical in the diagnosis of autoimmune diseases than conventional approaches, and we are looking forward to providing our customers with this improved service.”

Medipan develops and distributes in-vitro diagnostic tests, predominantly in the field of autoimmunity. Medipan's product portfolio provides a wide range of assays and it is expanding continuously. The company offers technical, medical, and scientific expertise and support ensuring the success of their partner's clinical and business objectives.


Related Links:
Pronostics
Medipan

Gold Member
12-Channel ECG
CM1200B
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Blanket Warming Cabinet
EC250
New
Plasma Freezer
iBF125-GX

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024